[Studies on amikacin (BB-K8) (author's transl)].
D000328:Adult; D000613:Aminobutyrates / Q000031:analogs & derivatives / Q000627:therapeutic use; D000653:Amniotic Fluid / Q000378:metabolism; D001424:Bacterial Infections / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004755:Enterobacteriaceae / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D007711:Klebsiella pneumoniae / Q000187:drug effects; D007743:Labor, Obstetric; D008413:Mastitis / Q000188:drug therapy; D008431:Maternal-Fetal Exchange; D008826:Microbial Sensitivity Tests; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D011247:Pregnancy; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects; D014511:Uremia / Q000378:metabolism; D014552:Urinary Tract Infections / Q000188:drug therapy; D014591:Uterine Diseases / Q000188:drug therapy; D014847:Vulvitis / Q000188:drug therapy
D000613:Aminobutyrates; D007612:Kanamycin